Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Inflammopharmacology. 2017 Aug;25(4):431-438. doi: 10.1007/s10787-017-0315-6. Epub 2017 Feb 8.

Effects of antirheumatic drug underutilization on rheumatoid arthritis disease activity.

Author information

1
Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan. maalqudah@just.edu.jo.
2
Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan.
3
Department of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan.

Abstract

BACKGROUND:

Following the recommended guidelines is crucial for achieving patient remission in rheumatoid arthritis. The aim of this study was to assess the effect of proper drug utilization of antirheumatic drugs on disease activity and drug safety in Jordan.

METHODS:

In a retrospective cross-sectional study, patient's demographics, clinical variables, drug regimens and side effects were recorded and the 28-joint disease activity scores were calculated. Patients were stratified into high, moderate, low disease activity or remission group.

RESULTS:

Around 80% of patients were using methotrexate which was under-dosed in 82% of them. Only 25% were using biologic drugs. Surprisingly, only 10% of patients had low disease activity and only 4% were in a remission state. Anaemia (32.3%) and mild renal impairment (27.6%) were the most common side effects.

CONCLUSIONS:

The low frequency of well-controlled disease activity is interpreted by high occurrence of methotrexate underdosing and biologic agent underprescription. Implementing the role of a clinical pharmacist could have a real impact on tight control of such disease issues in Jordan.

KEYWORDS:

Biologic agents; DMARDs; Disease activity; Rheumatoid arthritis; Side effects; Underdosing; Underprescription

PMID:
28176199
DOI:
10.1007/s10787-017-0315-6
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center